



Robert Greene Sterne
Jorge A. Goldstein
David K.S. Cornwell
Robert W. Tinsford
Tracy-Gene G. Durkin
Michelle A. Cimbal
Michael B. Ray
Robert E. Solzhi
Eric K. Steffe
Michael Q. Lee
Steven R. Ludwig
John M. Covert
Linda E. Hume
Robert C. Millington
Donald J. Featherstone
Timothy J. Shea, Jr.
Michael V. Messinger
Judith U. Kim

Patrick E. Garrett
Jeffrey T. Hevey
Heidi L. Kraus
Edina L. Ellison
Thomas C. Fiala
Donald R. Banowitz
Peter A. Jackson
Jeffrey S. Weaver
Brian J. Del Buono
Edward W. Yee
Vincent L. Capuano
Virgil Lee Beaton
Theodore A. Wood
Elizabeth J. Haines
Joseph S. Ostroff
Frank R. Cunningham
Rae Lynn P. Gural
Daniel A. Klein

Jason D. Eisenberg
Michael D. Specht
Tracy L. Muller
Jon E. Wright
LaNene M. DeSantis
Ann E. Summerfield
Helen C. Carlson
Cynthia M. Boucher
Timothy A. Doyle
Gabby L. Longworth
Lori A. Gordon
Laura A. Vogel
Bryan S. Wolfe
Basil M.S. Ali
Shannon A. Carroll
Matthew E. Kiley
Michelle E. Holubek
Marsha A. Rose

Young Tang
Christopher J. Walsh
W. State Coblenz
James J. Pelt
John T. Harn
Mark W. Rygel
Kevin W. McCabe
Registered Patent Agents*
Karen R. Makowicz
Matthew J. Dowd
Karinna Yujuan Pui Quach
Bryan L. Stanton
Robert A. Schwartzman
Victoria S. Rutherford
Simon J. Elliott
Julie A. Heider
Mita Mukherjee

Scott M. Woodhouse
Liliana Di Nola-Baron
Peter A. Socarras
Jeffrey K. Mills
Danielle L. Letting
Lori Brandes
Steven C. Oppenheimer
Cl. Counsel
Edward J. Kozlowski
Kenneth C. Bass III
Marvin C. Guthrie

*Admitted only in Maryland
*Admitted only in Virginia
*Practice limited to
Federal Agencies

July 14, 2006

WRITER'S DIRECT NUMBER:
(202) 771-8822
INTERNET ADDRESS:
SCARROLL@SKGF.COM

Commissioner for Patents
PO Box 1450
Alexandria, VA 22313-1450

Attn: Mail Stop Amendment

Re: U.S. Utility Patent Application 10/567,381
(U.S. Nat'l Phase of PCT/US2004/002702; Int'l Filing Date: January 30, 2004)
For: **Nogo Receptor Antagonists**
Inventors: **LEE et al.**
Our Ref: **2159.0430002/EJH/SAC**

Sir:

Transmitted herewith for appropriate action are the following documents:

1. Transmittal Letter to the United States Designated/Elected Office (DO/EO/US) Concerning a Submission Under 35 U.S.C. 371;
2. Information Disclosure Statement Filing under 37 C.F.R. § 1.97(b);
3. A listing of the cited documents on Form PTO/SB/08A (2 sheets);
4. A listing of the cited documents on Form PTO/SB/08B (3 sheets);
5. A copy of the cited documents FP1-FP16;
6. A copy of the cited documents NPL1-NPL25;
7. First Supplemental Information Disclosure Statement Filing under 37 C.F.R. § 1.97(b);
8. A listing of the cited documents on Form PTO/SB/08A (1 sheet);
9. A listing of the cited documents on Form PTO/SB/08B (2 sheets);
10. A copy of the cited documents NPL26-NPL36; and

Commissioner for Patents

July 14, 2006

Page 2

11. One (1) return postcard.

It is respectfully requested that the attached postcard be stamped with the date of filing of these documents, and that it be returned to our courier. In the event that extensions of time are necessary to prevent abandonment of this patent application, then such extensions of time are hereby petitioned.

The U.S. Patent and Trademark Office is hereby authorized to charge any fee deficiency, or credit any overpayment, to our Deposit Account No. 19-0036.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.



Shannon A. Carroll, Ph.D.
Attorney for Applicants
Registration No. 58,240

SAC/jk
Enclosures

556559

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

LEE *et al.*Appl. No.: 10/567,381 (*National Phase of
PCT/US2004/002702*)

I.A. Filed: January 30, 2004

For: **Nogo Receptor Antagonists**

Confirmation No.: 9649

Art Unit: *To be assigned*Examiner: *To be assigned*

Atty. Docket: 2159.0430002/EJH/SAC

**Information Disclosure Statement
Filing under 37 C.F.R. § 1.97(b)***Mail Stop Amendment*Commissioner for Patents
PO Box 1450
Alexandria, VA 22313-1450

Sir:

Listed on accompanying Forms PTO/SB/08A and PTO/SB/08B are documents that may be considered material to the examination of this application, in compliance with the duty of disclosure requirements of 37 C.F.R. §§ 1.56, 1.97 and 1.98.

Copies of documents **FP1-FP16** and **NPL1-NPL25** are submitted. However, in accordance with 37 C.F.R. § 1.98(a)(2), copies of U.S. patents and patent application publications, documents **US1-US22**, cited on the attached Form PTO/SB/08A are not submitted.

In accordance with 37 C.F.R. § 1.98(a)(3), Applicants' undersigned representative submits the following discussion of the relevance of the non-English language document **FP10** cited on Form PTO/SB/08A:

Document **FP10**, WO 93/01288 A1, is in a foreign language. The relevance of document **FP10** may be found in the English language abstract included on the face page of said document.

- 2 -

LEE *et al.*
Appl. No. 10/567,381
(National Phase of PCT/US2004/002702)

The Examiner's attention is directed to the following U.S. Patent Applications and PCT Patent Applications, which are directed to related technical subject matter:

U.S. Patent Application No. 09/758,140 inventor Strittmatter S.M., filed January 12, 2001; published as US 2002/0012965 A1, cited herein as document **US19**;

U.S. Patent Application No. 09/972,599, inventor Strittmatter S.M., filed October 6, 2001; published as US2002/0077295 A1, cited herein as document **US20**;

U.S. Patent Application No. 09/972,546, inventors Strittmatter *et al.*, filed October 6, 2001; published as US2003/0124704 A1, cited herein as document **US21**;

U.S. Patent Application No. 10/735,256, inventors Strittmatter *et al.*, filed December 12, 2003; published as US2005/0048520 A1, cited herein as document **US22**;

PCT Patent Application No. PCT/US01/01041, applicant Yale University, filed January 12, 2001, published as WO 01/51520 A2, cited herein as document **FP11**;

PCT Patent Application No. PCT/US01/31488, applicants Yale University and Biogen, Inc., filed October 06, 2001, published as WO 02/29059 A2, cited herein as document **FP12**;

PCT Patent Application No. PCT/US02/32007, applicant Yale University, filed October 04, 2002, published as WO 03/031462 A2, cited herein as document **FP13**;

PCT Patent Application No. PCT/US2003/025004, applicant Yale University and Biogen, Inc., filed August 07, 2003, published as WO 04/014311 A2, cited herein as document **FP14**;

PCT Patent Application No. PCT/US2004/011728, applicants and inventors Strittmatter *et al.*, filed April 16, 2004, published as WO 04/093893 A2, cited herein as document **FP15**; and

Atty. Dkt. No. 2159.0430002/EJH/SAC

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /SLW/

- 3 -

LEE *et al.*
Appl. No. 10/567,381
(National Phase of PCT/US2004/002702)

PCT Patent Application No. PCT/US04/002702, applicants and inventors Lee *et al.*, filed January 30, 2004, published as WO 05/016955 A2, cited herein as document **FP16**.

Where the publication date of a listed document does not provide a month of publication, the year of publication of the listed document is sufficiently earlier than the effective U.S. filing date and any foreign priority date so that the month of publication is not in issue. Applicants have listed publication dates on the attached IDS Forms based on information presently available to the undersigned. However, the listed publication dates should not be construed as an admission that the information was actually published on the date indicated.

Applicants reserve the right to establish the patentability of the claimed invention over any of the information provided herewith, and/or to prove that this information may not be prior art, and/or to prove that this information may not be enabling for the teachings purportedly offered.

This statement should not be construed as a representation that a search has been made, or that information more material to the examination of the present patent application does not exist. The Examiner is specifically requested not to rely solely on the material submitted herewith.

This Information Disclosure Statement is being filed before the mailing date of a first Office Action on the merits. No statement or fee is required.

It is respectfully requested that the Examiner initial and return copies of the enclosed IDS Forms, and indicate in the official file wrapper of this patent application that the documents have been considered.

Atty. Dkt. No. 2159.0430002/EJH/SAC

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /SLW/


- 4 -

LEE *et al.*
Appl. No. 10/567,381
(National Phase of PCT/US2004/002702)

The U.S. Patent and Trademark Office is hereby authorized to charge any fee deficiency, or credit any overpayment, to our Deposit Account No. 19-0036.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.



Shannon A. Carroll, Ph.D.
Attorney for Applicants
Registration No. 58,240

Date: July 14, 2006
1100 New York Avenue, N.W.
Washington, D.C. 20005-3934
(202) 371-2600

526729_1.DOC

Atty. Dkt. No. 2159.0430002/EJH/SAC

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /SLW/

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

LEE *et al.*Appl. No.: 10/567,381 (*National Phase of
PCT/US2004/002702*)

I.A. Filed: January 30, 2004

For: **Nogo Receptor Antagonists**

Confirmation No.: 9649

Art Unit: *To be assigned*Examiner: *To be assigned*

Atty. Docket: 2159.0430002/EJH/SAC

**First Supplemental Information Disclosure Statement
Filing under 37 C.F.R. § 1.97(b)***Mail Stop Amendment*

Commissioner for Patents

PO Box 1450

Alexandria, VA 22313-1450

Sir:

Listed on accompanying Forms PTO/SB/08A and PTO/SB/08B are documents that may be considered material to the examination of this application, in compliance with the duty of disclosure requirements of 37 C.F.R. §§ 1.56, 1.97 and 1.98. The numbering on this First Supplemental Information Disclosure Statement is a continuation of the numbering in Applicants' Information Disclosure Statement filed herewith in connection with the above-captioned application.

Copies of documents **NPL26-NPL36** are submitted. However, in accordance with 37 C.F.R. § 1.98(a)(2), copies of U.S. patents and patent application publications, documents **US23-US28**, cited on the attached Form PTO/SB/08A are not submitted.

The Examiner's attention is directed to the following U.S. Patent Application, which is directed to related technical subject matter:

- 2 -

LEE *et al.*
Appl. No. 10/567,381
(National Phase of PCT/US2004/002702)

U.S. Patent Application No. 11/055,163, inventors Lee *et al.*, filed February 10, 2005; published as US2005/0271655 A1, cited herein as document US28;

Where the publication date of a listed document does not provide a month of publication, the year of publication of the listed document is sufficiently earlier than the effective U.S. filing date and any foreign priority date so that the month of publication is not in issue. Applicants have listed publication dates on the attached IDS Forms based on information presently available to the undersigned. However, the listed publication dates should not be construed as an admission that the information was actually published on the date indicated.

Applicants reserve the right to establish the patentability of the claimed invention over any of the information provided herewith, and/or to prove that this information may not be prior art, and/or to prove that this information may not be enabling for the teachings purportedly offered.

This statement should not be construed as a representation that a search has been made, or that information more material to the examination of the present patent application does not exist. The Examiner is specifically requested not to rely solely on the material submitted herewith.

This Information Disclosure Statement is being filed before the mailing date of a first Office Action on the merits. No statement or fee is required.

Atty. Dkt. No. 2159.0430002/EJH/SAC

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /SLW/

- 3 -

LEE *et al.*
Appl. No. 10/567,381
(National Phase of PCT/US2004/002702)

It is respectfully requested that the Examiner initial and return copies of the enclosed IDS Forms, and indicate in the official file wrapper of this patent application that the documents have been considered.

The U.S. Patent and Trademark Office is hereby authorized to charge any fee deficiency, or credit any overpayment, to our Deposit Account No. 19-0036.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.



Shannon A. Carroll, Ph.D.
Attorney for Applicants
Registration No. 58,240

Date: July 14, 2006
1100 New York Avenue, N.W.
Washington, D.C. 20005-3934
(202) 371-2600

526895_1.DOC

Atty. Dkt. No. 2159.0430002/EJH/SAC

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /SLW/

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				<p align="center">Complete if Known</p> <table border="1"> <tr> <td>Application Number</td> <td>10/567,381 (Original Phase of PCT/US2004/002702)</td> </tr> <tr> <td>I.A. Filing Date</td> <td>January 30, 2004</td> </tr> <tr> <td>First Named Inventor</td> <td>Lee, Daniel H.S.</td> </tr> <tr> <td>Art Unit</td> <td>To be assigned</td> </tr> <tr> <td>Examiner Name</td> <td>To be assigned Sandra Wegert</td> </tr> <tr> <td>Attorney Docket Number</td> <td>2159.0430002/EJH/SAC</td> </tr> </table>		Application Number	10/567,381 (Original Phase of PCT/US2004/002702)	I.A. Filing Date	January 30, 2004	First Named Inventor	Lee, Daniel H.S.	Art Unit	To be assigned	Examiner Name	To be assigned Sandra Wegert	Attorney Docket Number	2159.0430002/EJH/SAC
Application Number	10/567,381 (Original Phase of PCT/US2004/002702)																
I.A. Filing Date	January 30, 2004																
First Named Inventor	Lee, Daniel H.S.																
Art Unit	To be assigned																
Examiner Name	To be assigned Sandra Wegert																
Attorney Docket Number	2159.0430002/EJH/SAC																
Sheet	1	of	1														

[illegible][illegible]

526755 1.DOC

Examiner Signature	/Sandra Wegert/	Date Considered	11/04/2010
-----------------------	-----------------	--------------------	------------

* EXAMINER: Initial if reference considered whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. * Applicant's unique citation designation number (optional). * See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. * Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). * For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. * Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. * Applicant is to place a check mark here if English language translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /SLW/

PTO/SB/08B (07-05)

Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				Complete if Known	
FIRST SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Application Number	10/567,381 (National Phase of PCT/US2004/002702)
				I.A. Filing Date	January 30, 2004
				First Named Inventor	Lee, Daniel H.S.
				Art Unit	To be assigned
				Examiner Name	To be assigned
				Attorney Docket Number	2159.0430002/EJH/SAC
Sheet	1	of	2		

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume issue number(s), publisher, city and/or country where published	T ²	
	NPL26	Fournier, A.E., <i>et al.</i> , "Characterization of the neuronal receptor mediating Nogo-66 inhibition of axonal regeneration," <i>J. Neurochem.</i> 78 (Suppl. 1):105, Blackwell Publishing, Abstract No. S08-01 (September 2001)		
	NPL27	Fournier, A.E., <i>et al.</i> , "Nogo Receptor Domain Analysis," <i>Society for Neuroscience Abstracts</i> 27:670, Society for Neuroscience, Abstract No. 258.3, presented at the <i>Society for Neuroscience's 31st Annual Meeting</i> , San Diego, CA (November 12, 2001)		
	NPL28	GrandPre, T.J., <i>et al.</i> , "Functional Analysis of Nogo-66 and Nogo Receptor Domains," <i>Society for Neuroscience Abstracts</i> 27:670, Society for Neuroscience, Abstract No. 258.4, presented at the <i>Society for Neuroscience's 31st Annual Meeting</i> , San Diego, CA (November 12, 2001)		
	NPL29	International Search Report for International Application No. PCT/US2005/002535, European Patent Office, Netherlands, mailed October 24, 2005		
	NPL30	International Search Report for International Application No. PCT/US05/35719, ISA/US, Alexandria, VA, mailed April 13, 2006		
	NPL31	International Search Report for International Application No. PCT/US2004/02702, ISA/US, Alexandria, VA, mailed April 20, 2006		
	NPL32	Li, M., <i>et al.</i> , "Effect of soluble Nogo receptor treatment on functional and histological outcome after spinal cord injury in the rat," <i>Biosis Database</i> , Accession No. PREV200400194121, Abstract No. 80.22, Presented at the <i>33rd Annual Meeting of the Society of Neuroscience</i> , New Orleans, LA (November 8-12, 2003)		
	NPL33	Li, W., <i>et al.</i> , "A Neutralizing Anti-Nogo66 Receptor Monoclonal Antibody Reverses Inhibition of Neurite Outgrowth by Central Nervous System Myelin," <i>J. Biol. Chem.</i> 42:43780-43788, The American Society for Biochemistry and Molecular Biology, Inc. (October 2004)		
	NPL34	Li, W., <i>et al.</i> , "Neutralization of NGR1 May Be Sufficient to Promote Rat DRG Neurite Outgrowth in the Presence of CNS Myelin," <i>SFN 2003 Abstract Viewer & Itinerary Planner</i> , Program No. 678.3, Presented at the <i>33rd Annual Meeting of the Society of Neuroscience</i> , New Orleans, LA (November 8-12, 2003)		

Examiner Signature	/Sandra Wegert/	Date Considered	11/04/2010
-----------------------	-----------------	--------------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /SLW/

Substitute for form 1449/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Application Number	10/567,381 (National Phase of PCT/US2004/002702)
				I.A. Filing Date	January 30, 2004
				First Named Inventor	Lee, Daniel H.S.
				Art Unit	To be assigned
				Examiner Name	To be assigned
Sheet	1	of	2	Attorney Docket Number	2159.0430002/EJH/SAC

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number Number-Kind Code* (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	
	US1	3,817,837	06/18/1974	Rubenstein <i>et al.</i>	
	US2	3,850,752	11/26/1974	Schuurs <i>et al.</i>	
	US3	3,939,350	02/17/1976	Kronick <i>et al.</i>	
	US4	3,996,345	12/07/1976	Ullman <i>et al.</i>	
	US5	4,275,149	06/23/1981	Litman <i>et al.</i>	
	US6	4,277,437	07/07/1981	Maggio	
	US7	4,366,241	12/28/1982	Tom <i>et al.</i>	
	US8	4,399,216	08/16/1983	Axel <i>et al.</i>	
	US9	4,510,245	04/09/1985	Cousens <i>et al.</i>	
	US10	4,634,665	01/06/1987	Axel <i>et al.</i>	
	US11	4,816,567	03/28/1989	Cabilly <i>et al.</i>	
	US12	4,968,615	11/06/1990	Koszinowski <i>et al.</i>	
	US13	5,168,062	12/01/1992	Stinski	
	US14	5,179,017	01/12/1993	Axel <i>et al.</i>	
	US15	5,223,409	06/29/1993	Ladner <i>et al.</i>	
	US16	5,877,293	03/02/1999	Adair <i>et al.</i>	
	US17	5,886,152	03/23/1999	Nakatani <i>et al.</i>	
	US18	6,054,297	04/25/2000	Carter <i>et al.</i>	
	US19	US2002/0012965 A1	01/31/2002	Strittmatter	
	US20	US2002/0077295 A1	06/20/2002	Strittmatter	

FOREIGN PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Foreign Patent Document Country Code* Number* Kind Code* (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	
	FP1	EP 0 216 846 B1	01/10/1990	CellTech Limited	
	FP2	EP 0 256 055 B1	08/28/1991	CellTech Limited	
	FP3	EP 0 323 997 B1	04/21/1993	CellTech Limited	
	FP4	WO 91/17271 A1	11/14/1991	Affymax Technologies N.V.	
	FP5	WO 92/01047 A1	01/23/1992	Cambridge Antibody Technology Limited	
	FP6	WO 92/09690 A2	06/11/1992	Genentech, Inc.	
	FP7	WO 92/15679 A1	09/17/1992	Protein Engineering Corporation	
	FP8	WO 92/18619 A1	10/29/1992	The Scripps Research Institute	
	FP9	WO 92/20791 A1	11/26/1992	Cambridge Antibody Technology Limited	
	FP10	WO 93/01288 A1	01/21/1993	Deutsches Krebsforschungszentrum Stiftung Des Öffentlichen Rechts	
	FP11	WO 01/51520 A2	07/19/2001	Yale University	
	FP12	WO 02/29059 A2	04/11/2002	Yale University; Biogen, Inc.	

Examiner Signature	/Sandra Wegert/	Date Considered	11/04/2010
--------------------	-----------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. *Applicant's unique citation designation number (optional). *See Kinde Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. *Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). *For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. *Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. *Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9198 (1-800-786-9198) and select option 2.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /SLW/

526736 1.DOC

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation not in conformance and not considered. Include copy of this form with next communication to applicant. *Applicant's unique citation designation number (optional). *See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. *Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). *For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. *Kind of publication. *Indicate the language of the document as indicated on the document under WIPO Standard ST.16 if possible. *Applicant is to place a check mark here if an English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, USPTO, Attention: Paperwork Project Manager, P.O. Box 1500, Alexandria, VA 22313-1500. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /SLW/

PTO/SB/08B (08-03)

Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Application Number	10/567,381 (National Phase of PCT/US2004/002702)
				I.A. Filing Date	January 30, 2004
				First Named Inventor	Lee, Daniel H.S.
				Art Unit	To be assigned
				Examiner Name	To be assigned
				Attorney Docket Number	2159.0430002/EJH/SAC
Sheet	1	of	3		

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume number, publisher, city and/or country where published	T ²		
	NPL1	Basso, D.M., <i>et al.</i> , "MASCIS Evaluation of Open Field Locomotor Scores: Effects of Experience and Teamwork on Reliability," <i>J. Neurotrauma</i> 13:343-359, Mary Ann Liebert, Inc. (1996)			
	NPL2	Brittis, P.A. and Flanagan, J.G., "Nogo Domains and a Nogo Receptor: Implications for Axon Regeneration," <i>Neuron</i> 30:11-14, Cell Press (April 2001)			
	NPL3	Chen, M.S., <i>et al.</i> , "Nogo-A is a myelin-associated neurite outgrowth inhibitor and an antigen for monoclonal antibody IN-1," <i>Nature</i> 403:434-439, Macmillan Magazines Ltd. (2000)			
	NPL4	Domeniconi, M., <i>et al.</i> , "Myelin-Associated Glycoprotein Interacts with the Nogo66 Receptor to Inhibit Neurite Outgrowth," <i>Neuron</i> 35:283-290, Cell Press (July 2002)			
	NPL5	Fournier, A.E., <i>et al.</i> , "Identification of a receptor mediating Nogo-66 inhibition of axonal regeneration," <i>Nature</i> 409:341-346, Macmillan Magazines Ltd. (January 2001)			
	NPL6	Fournier, A.E., <i>et al.</i> , "Truncated Soluble Nogo Receptor Binds Nogo-66 and Blocks Inhibition of Axon Growth by Myelin," <i>J. Neurosci.</i> 22:8876-8883, Society of Neuroscience with the assistance of Stanford University's HighWire Press™ (October 2002)			
	NPL7	Grandpré, T., <i>et al.</i> , "Identification of the Nogo inhibitor of axon regeneration as a Reticulon protein," <i>Nature</i> 403:439-444, Macmillan Magazines Ltd. (2000)			
	NPL8	Grandpré, T., <i>et al.</i> , "Nogo-66 receptor antagonist peptide promotes axonal regeneration," <i>Nature</i> 417:547-551, Nature Publishing Group (May 2002)			
	NPL9	Grimpe, B., <i>et al.</i> , "The Critical Role of Basement Membrane-Independent Laminin γ 1 Chain during Axon Regeneration in the CNS," <i>J. Neurosci.</i> 22:3144-3160, Society for Neuroscience with the assistance of Stanford University's HighWire Press™ (April 2002)			
	NPL10	Jones, L.L., <i>et al.</i> , "NG2 Is a Major Chondroitin Sulfate Proteoglycan Produced after Spinal Cord Injury and Is Expressed by Macrophages and Oligodendrocyte Progenitors," <i>J. Neurosci.</i> 22:2792-2803, Society for Neuroscience with the assistance of Stanford University's HighWire Press™ (April 2002)			
Examiner Signature	/Sandra Wegert/			Date Considered	11/04/2010

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

ALL REFERENCES CONSIDERED REVIEWED WHERE LINED THROUGH. /SLW/

PTO/SB/088 (08-03)

Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Application Number	10/567,381 (National Phase of PCT/US2004/002702)
				I.A. Filing Date	January 30, 2004
				First Named Inventor	Lee, Daniel H.S.
				Art Unit	To be assigned
				Examiner Name	To be assigned
Sheet	2	of	3	Attorney Docket Number	2159.0430002/EJH/SAC

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume number, publisher, city and/or country where published		T ²	
	NPL11	Li, M., et al., "Functional Role and Therapeutic Implications of Neuronal Caspase-1 and -3 in a Mouse Model of Traumatic Spinal Cord Injury," <i>Neurosci.</i> 99:333-342, Elsevier Science Ltd. (2000)			
	NPL12	Li, S. and Strittmatter, S.M., "Delayed Systemic Nogo-66 Receptor Antagonist Promotes Recovery from Spinal Cord Injury," <i>J. Neurosci.</i> 23:4219-4227, Society for Neuroscience with the assistance of Stanford University's HighWire Press™ (May 2003)			
	NPL13	Liu, B.P., et al., "Myelin-Associated Glycoprotein as a Functional Ligand for the Nogo-66 Receptor," <i>Science</i> 297:1190-1193, American Association for the Advancement of Science (published online June 27, 2002)			
	NPL14	Liu, Y., et al., "Transplants of Fibroblasts Genetically Modified to Express BDNF Promote Regeneration of Adult Rat Rubrospinal Axons and Recovery of Forelimb Function," <i>J. Neurosci.</i> 19:4370-4387, Society for Neuroscience with the assistance of Stanford University's HighWire Press™ (1999)			
	NPL15	McKerracher, L., et al., "Identification of Myelin-Associated Glycoprotein as a Major Myelin-Derived Inhibitor of Neurite Growth," <i>Neuron</i> 13:805-811, Cell Press (1994)			
	NPL16	Metz, G.A.S., et al., "Efficient testing of motor function in spinal cord injured rats," <i>Brain Res.</i> 883:165-177, Elsevier Science B.V. (2000)			
	NPL17	Mikol, D.D. and Stefansson, K., "A Phosphatidylinositol-linked Peanut Agglutinin-binding Glycoprotein in Central Nervous System Myelin and on Oligodendrocytes," <i>J. Cell. Biol.</i> 106:1273-1279, The Rockefeller University Press (1988)			
	NPL18	Mukhopadhyay, G., et al., "A Novel Role for Myelin-Associated Glycoprotein as an Inhibitor of Axonal Regeneration," <i>Neuron</i> 13:757-767, Cell Press (1994)			
	NPL19	Noël, D., et al., "High In Vivo Production of a Model Monoclonal Antibody on Adenoviral Gene Transfer," <i>Human Gene Therapy</i> 13:1483-1493, Mary Ann Liebert, Inc. (August 2002)			
	NPL20	Ramon-Cueto, A., et al., "Functional Recovery of Paraplegic Rats and Motor Axon Regeneration in Their Spinal Cords by Olfactory Ensheathing Glia," <i>Neuron</i> 25:425-435, Cell Press (2000)			
Examiner Signature	/Sandra Wegert/			Date Considered	11/04/2010

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

ALL REFERENCES CONSIDERED AND CITED WHERE LINED THROUGH. /SLW/

PTO/SB/088 (08-03)

Approved for use through 07/31/2006, OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Application Number	10/567,381 (National Phase of PCT/US2004/002702)
				I.A. Filing Date	January 30, 2004
				First Named Inventor	Lee, Daniel H.S.
				Art Unit	To be assigned
				Examiner Name	To be assigned
				Attorney Docket Number	2159.0430002/EJH/SAC
Sheet	3	of	3		

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume number, publisher, city and/or country where published	T ²	
	NPL21	Rutishauser, U. and Jessell, T.M., "Cell Adhesion Molecules in Vertebrate Neural Development," <i>Physiol. Rev.</i> 68:819-857, the American Physiological Society (1988)		
	NPL22	Wang, K.C., <i>et al.</i> , "Oligodendrocyte-myelin glycoprotein is a Nogo receptor ligand that inhibits neurite outgrowth," <i>Nature</i> 417:941-944, Nature Publishing Group (June 2002)		
	NPL23	Wang, X., <i>et al.</i> , "Localization of Nogo-A and Nogo-66 Receptor Proteins at Sites of Axon-Myelin and Synaptic Contact," <i>J. Neurosci.</i> 22:5505-5515, Society for Neuroscience with the assistance of Stanford University's HighWire Press™ (July 2002)		
	NPL24	Wang, H.-Y., <i>et al.</i> , "Amyloid Peptide A β_{1-42} Binds Selectively and with Picomolar Affinity to $\alpha 7$ Nicotinic Acetylcholine Receptors," <i>J. Neurochem.</i> 75:1155-1161, Lippincott Williams & Wilkins, Inc. (2000)		
	NPL25	Weidner, N., <i>et al.</i> , "Spontaneous corticospinal axonal sprouting and functional recovery after adult central nervous system injury," <i>Proc. Natl. Acad. Sci. USA</i> 98:3513-3518, The National Academy of Sciences (March 2001)		

526740_1.DOC

Examiner Signature	/Sandra Wegert/	Date Considered	11/04/2010
-----------------------	-----------------	--------------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /SLW/